{
    "organizations": [],
    "uuid": "a0a5087ce2d5732abb10456df3b3f6ce86979d8b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fibrocell-reports-on-interim-resul/brief-fibrocell-reports-on-interim-results-and-progress-of-phase-1-2-clinical-trial-of-fcx-007-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-idUSASC0A304",
    "ord_in_thread": 0,
    "title": "BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Fibrocell Science Inc:\n* FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA\n* FIBROCELL SCIENCE INC - FCX-007 WELL-TOLERATED UP TO 52 WEEKS POST-ADMINISTRATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T19:18:00.000+03:00",
    "crawled": "2018-05-22T19:26:16.032+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "fibrocell",
        "science",
        "inc",
        "fibrocell",
        "report",
        "interim",
        "result",
        "progress",
        "phase",
        "clinical",
        "trial",
        "gene",
        "therapy",
        "recessive",
        "dystrophic",
        "epidermolysis",
        "bullosa",
        "fibrocell",
        "science",
        "inc",
        "week",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}